ESTRO Multidisciplinary Management of Breast Cancer 2017

Tamoxifen vs aromatase inhibitors

Differences

OR (AI vs TAM)

Absolute risk ( ) difference

NNH

Cardio vasc disease Hyper cholesterol

1.26 (1.10-1.43) 2.36 (2.15-2.60)

4,2 vs 3,4% (0.8%)

132

Thrombosis

0.55(0.46-0.64)

1,6 vs 2,8% (1.2%) 79

Bone fractures

1.47(1.34-1.61)

7,5 vs 5,2% (2.3%) 46

Endometrial cancer 0.34(0.22-0.53)

0,1 vs 0,5% (0.4%) 258

NNH: number needed to harm

Amir et al, JNCI 2011